RxDoctor Payments Data

William Kinnett

Acute Care · Cordele, GANPI 1194383075

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,277 of the $5,881 with a category attached, or 72.7%. 16 manufacturers reported payments, led by Gilead at 57.2% of the total. Reporting peaked in 2022 at $2,505 and has fallen 99.1% since, to $23 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,881in general payments, 2019–2025

Across 136 payments — averaging $43.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$834
  • Janssen Products, LP$328
  • AstraZeneca$265
  • Merck$217
  • Sumitomo Pharma America, Inc.$125
  • plus $748 from 10 others

What the payments were for

  • Consulting fees$1,07018%
  • Travel & lodging$4307%
  • Food & beverage$4,27773%
  • Education$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,881 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala136$565,118
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf17$89,083
DescovyEmtricitabine/Tenofov Alafenam16$39,357
MicafunginMicafungin Sodium15$6,267
Vancomycin Hcl12$2,084
Rifampin11$1,131
CeftriaxoneCeftriaxone Sodium17$655
Doxycycline Hyclate29$433
Cephalexin23$374
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$147
FenofibrateFenofibrate Nanocrystallized11$99
Fluconazole22$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,365$604,476152 claims
Janssen Products, LPSymtuza$328$89,08317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.

Other acute care in Cordele

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →